Close Menu
Fund Focus News
    Facebook X (Twitter) Instagram
    Trending
    • ‘He just looked like he took drugs’: Donald Trump says Barry Bonds Hall of Fame case is ‘different’ from Roger Clemens
    • If I Could Only Hold 1 ETF Through the Next Stock Market Crash, Here’s What I’d Buy
    • Investors Put $45.7 Billion Into U.S. Stock Funds Right Before the Stock Market Tanked
    • If the S&P 500 Drops by 20%, I’m Buying These 3 ETFs Without Hesitation
    • Bunbury Scouts to stage Christmas Raffle to raise key funds
    • Are all index-named mutual funds recommended? Look at the Sharpe ratio, not just the yield.
    • Looking Back at Every James Bond’s First Outing
    • Is It Better to Sip Water Throughout the Day or Drink a Lot at Once? Experts Explain
    Facebook X (Twitter) Instagram
    Fund Focus News
    • Home
    • Bonds
    • ETFs
    • Funds
    • Investments
    • Mutual Funds
    • Property Investments
    • SIP
    Fund Focus News
    Home»Investments»GLP-1s are driving returns on R&D investments for Big Pharma, report says
    Investments

    GLP-1s are driving returns on R&D investments for Big Pharma, report says

    March 25, 2025


    In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023 in Los Angeles, California. - Image: Mario Tama / Staff (Getty Images)
    In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023 in Los Angeles, California. – Image: Mario Tama / Staff (Getty Images)

    Big Pharma is expected to see big returns from its investment in a class of drugs made famous by Novo Nordisk’s (NVO) popular diabetes drug Ozempic.

    Deloitte’s annual report, Measuring the Return from Pharmaceutical Innovation, found that GLP-1 drugs could fuel significant returns on research and development investments made last year by major drugmakers. The consulting firm analyzed the projected internal rate of return for late-stage pipeline assets across the 20 leading pharma companies.

    On average, these companies forecast peak sales of $510 million per asset. But when GLP-1s are excluded, that figure drops sharply to $370 million. The internal rate of return for late-stage pipeline assets climbed from 5.9% in 2024, from 4.1% in 2023 — again driven in large part by GLP-1 drugs. Without them, returns would have declined, dipping to 3.8% in 2024 and 3.4% in 2023.

    This matters even more given that the report also found that the average cost to develop a drug for Big Pharma was $2.23 billion in 2024, up from $2.12 billion the year before.

    GLP-1 drugs mimic hormones that regulate blood sugar and suppress appetite, making them highly sought after for treating obesity and Type 2 diabetes. The surging demand has propelled Eli Lilly (LLY) and Novo Nordisk into becoming the largest pharma companies in the world. Eli Lilly’s weight-loss drug Zepbound generated $4.9 billion in annual revenue, while Novo Nordisk’s rival treatment, Wegovy, reached roughly $8 billion in sales.

    Wall Street has taken notice. Since the U.S. Food and Drug Administration (FDA) approved Zepbound in November 2023, Eli Lilly’s stock has soared more than 40%, pushing its market capitalization past $750 billion. Novo Nordisk has seen an even steeper climb, with its stock rising over 76% since Wegovy’s launch in 2021.

    With such massive returns, several companies — including Novo Nordisk, Eli Lilly, Pfizer, and Amgen— are advancing next-generation GLP-1 drugs and investigating their potential for new uses, such as treating sleep apnea and improving heart health.

    For the latest news, Facebook, Twitter and Instagram.





    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email

    Related Posts

    Vinhomes plans $116 mln bond issue to finance investment projects

    November 21, 2026

    RMIG celebrates 125 years with ambitious investment plan

    November 21, 2026

    Egypt’s ECHEM Holds Workshop to Attract Investment in First Sustainable Aviation Fuel Project

    November 21, 2026
    Leave A Reply Cancel Reply

    Top Posts

    If I Could Only Hold 1 ETF Through the Next Stock Market Crash, Here’s What I’d Buy

    November 21, 2026

    ‘He just looked like he took drugs’: Donald Trump says Barry Bonds Hall of Fame case is ‘different’ from Roger Clemens

    November 21, 2026

    Investors Put $45.7 Billion Into U.S. Stock Funds Right Before the Stock Market Tanked

    November 21, 2026

    Stake, Rentify outline property technology plans at Dubai Future Week

    November 21, 2026
    Don't Miss
    Bonds

    ‘He just looked like he took drugs’: Donald Trump says Barry Bonds Hall of Fame case is ‘different’ from Roger Clemens

    November 21, 2026

    President Donald Trump has spent more than a year pushing for Pete Rose and Roger…

    If I Could Only Hold 1 ETF Through the Next Stock Market Crash, Here’s What I’d Buy

    November 21, 2026

    Investors Put $45.7 Billion Into U.S. Stock Funds Right Before the Stock Market Tanked

    November 21, 2026

    If the S&P 500 Drops by 20%, I’m Buying These 3 ETFs Without Hesitation

    November 21, 2026
    Stay In Touch
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo
    EDITOR'S PICK

    Jackie Bezos, mother of Amazon founder Jeff who gave her son funds to start his internet behemoth

    August 15, 2025

    Goldman Sachs to launch three tokenization projects by end of year, says digital assets chief: ‘A renewed momentum in crypto’

    July 11, 2024

    Rashed Darwish Al Ketbi commercial investments and Marriott International sign agreement to open The St. Regis Mirfa Beach Resort, Abu Dhabi

    November 3, 2025
    Our Picks

    ‘He just looked like he took drugs’: Donald Trump says Barry Bonds Hall of Fame case is ‘different’ from Roger Clemens

    November 21, 2026

    If I Could Only Hold 1 ETF Through the Next Stock Market Crash, Here’s What I’d Buy

    November 21, 2026

    Investors Put $45.7 Billion Into U.S. Stock Funds Right Before the Stock Market Tanked

    November 21, 2026
    Most Popular

    🔥Juve target Chukwuemeka, Inter raise funds, Elmas bid in play 🤑

    August 20, 2025

    💵 Libra responds after Flamengo takes legal action and ‘freezes’ funds

    September 26, 2025

    🇮🇸 CPP Investments and Equinix complete atNorth acquisition to support growth of leading Nordic data center platform

    September 1, 2026
    © 2026 Fund Focus News
    • Get In Touch
    • Privacy Policy
    • Terms and Conditions

    Type above and press Enter to search. Press Esc to cancel.